Cited by 49Neuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on BehaviorNicotinic Acetylcholine Receptors Study

Differential roles of GABAA receptor subtypes in benzodiazepine-induced enhancement of brain-stimulation reward

Open access
Reynolds, Lauren M, Engin, Elif, Tantillo, Gabriella, Lau, Hew Mun, Muschamp, John W, Carlezon, William A, Rudolph, Uwe·2012·Neuropsychopharmacology

Abstract

Benzodiazepines such as diazepam are widely prescribed as anxiolytics and sleep aids. Continued use of benzodiazepines, however, can lead to addiction in vulnerable individuals. Here, we investigate the neural mechanisms of the behavioral effects of benzodiazepines using the intracranial self-stimulation (ICSS) test, a procedure with which the reward-enhancing effects of these drugs can be measured. Benzodiazepines bind nonselectively to several different GABA(A) receptor subtypes. To elucidate the α subunit(s) responsible for the reward-enhancing effects of benzodiazepines, we examined mice carrying a histidine-to-arginine point mutation in the α1, α2, or α3 subunit, which renders the targeted subunit nonresponsive to diazepam, other benzodiazepines and zolpidem. In wild-type and α1-point-mutated mice, diazepam caused a dose-dependent reduction in ICSS thresholds (reflecting a reward-enhancing effect) that is comparable to the reduction observed following cocaine administration. This effect was abolished in α2- and α3-point-mutant mice, suggesting that these subunits are necessary for the reward-enhancing action of diazepam. α2 Subunits appear to be particularly important, since diazepam increased ICSS thresholds (reflecting an aversive-like effect) in α2-point-mutant animals. Zolpidem, an α1-preferring benzodiazepine-site agonist, had no reward-enhancing effects in any genotype. Our findings implicate α2 and α3 subunit containing GABA(A) receptors as key mediators of the reward-related effects of benzodiazepines. This finding has important implications for the development of new medications that retain the therapeutic effects of benzodiazepines but lack abuse liability.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/npp.2012.115

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Positive modulation of α2GABAARs is required for the reward-enhancing effects of benzodiazepines.

    “Moreover, positive modulation of α2GABAARs is required for the reward-enhancing effects of benzodiazepines [106], and α2GABAARs in the NAc are necessary to maintain midazolam preference in a two-bottle choice drinking test [107].”

    From An emerging circuit pharmacology of GABAA receptors (2018) · cites this paper as [106]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Reynolds, L. M., Engin, E., Tantillo, G., Lau, H. M., Muschamp, J. W., Carlezon, W. A., & Rudolph, U.
Affiliations
  • McLean Hospital (US)
  • Harvard University (US)
Corresponding author
Engin, Elif
Venue
Neuropsychopharmacology
Published
2012-07-04
Volume
37
Issue
11
Pages
2531-2540
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W2028283774
Cited by
49
References
58
Citations by year
2025: 2 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 5 · 2015: 6 · 2014: 10 · 2013: 3 · 2012: 2
FWCI
2.77
Type
journal article
Language
en
Open access
Locations
  • Neuropsychopharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute on Drug Abuse (R03DA026578)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Keywords
benzodiazepines, diazepam, GABAA receptor subtypes, intracranial self-stimulation, aversive effects, zolpidem, abuse liability
MeSH terms
Analysis of Variance, Animals, Behavior, Animal, Benzodiazepines, Brain, Cocaine, Dose-Response Relationship, Drug, Electric Stimulation, Male, Mice, Inbred C57BL, Mice, Transgenic, Receptors, GABA-A, Reinforcement Schedule, Reward, Self Stimulation, Point Mutation, GABA Agents, Dopamine Uptake Inhibitors, Protein Subunits, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review